Pura Vida Investments’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Pura Vida Investments’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-89,886	Closed	-$612K	–	288
2021 Q4	$612K	Sell	89,886 -24,457	-21%	-$167K	0.02%	205
2021 Q3	$834K	Sell	114,343 -28,777	-20%	-$247K	0.03%	231
2021 Q2	$1.43M	Sell	143,120 -93,191	-39%	-$834K	0.04%	170
2021 Q1	$2.26M	Buy	+236,311	New	+$2.32M	0.06%	154
2020 Q4	–	Sell	-148,949	Closed	-$1.32M	–	226
2020 Q3	$1.32M	Buy	+148,949	New	+$1.69M	0.07%	126

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pura Vida Investments's PSTX Position: Q1 2022 in Review

Pura Vida Investments sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2022, closing a stake of 89,886 shares — an estimated $612K sold.

Pura Vida Investments first reported a position in PSTX in Q3 2020 and held it in 5 quarters. The position peaked at $2.26M in Q1 2021. 64 funds tracked by Wall St. Rank hold PSTX as of Q1 2022.

Pura Vida Investments reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Pura Vida Investments sold 89,886 Poseida Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $612K.
Pura Vida Investments first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Pura Vida Investments's Poseida Therapeutics, Inc. Common Stock position peaked at $2.26M in Q1 2021.
64 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.